A detailed history of Ballentine Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 37,590 shares of ABBV stock, worth $6.6 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
37,590
Previous 31,987 17.52%
Holding current value
$6.6 Million
Previous $5.49 Million 35.31%
% of portfolio
0.13%
Previous 0.1%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$163.84 - $199.33 $917,995 - $1.12 Million
5,603 Added 17.52%
37,590 $7.42 Million
Q2 2024

Aug 06, 2024

BUY
$154.79 - $180.76 $109,591 - $127,978
708 Added 2.26%
31,987 $5.49 Million
Q1 2024

Apr 11, 2024

BUY
$159.82 - $182.1 $950,929 - $1.08 Million
5,950 Added 23.49%
31,279 $5.7 Million
Q4 2023

Jan 23, 2024

SELL
$137.6 - $154.97 $332,854 - $374,872
-2,419 Reduced 8.72%
25,329 $3.93 Million
Q3 2023

Oct 19, 2023

BUY
$133.59 - $154.65 $1.03 Million - $1.19 Million
7,685 Added 38.3%
27,748 $4.14 Million
Q2 2023

Jul 26, 2023

SELL
$132.51 - $164.9 $816,394 - $1.02 Million
-6,161 Reduced 23.49%
20,063 $2.7 Million
Q1 2023

Apr 27, 2023

BUY
$144.61 - $166.54 $963,247 - $1.11 Million
6,661 Added 34.05%
26,224 $4.18 Million
Q4 2022

Jan 27, 2023

BUY
$138.31 - $165.87 $263,203 - $315,650
1,903 Added 10.78%
19,563 $0
Q3 2022

Oct 26, 2022

BUY
$134.21 - $153.93 $371,761 - $426,386
2,770 Added 18.6%
17,660 $2.37 Million
Q2 2022

Aug 09, 2022

BUY
$137.62 - $174.96 $32,203 - $40,940
234 Added 1.6%
14,890 $2.28 Million
Q1 2022

May 05, 2022

SELL
$131.98 - $163.75 $7,918 - $9,825
-60 Reduced 0.41%
14,656 $2.38 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $169,846 - $214,905
1,581 Added 12.04%
14,716 $1.99 Million
Q3 2021

Oct 27, 2021

BUY
$106.4 - $120.78 $2,766 - $3,140
26 Added 0.2%
13,135 $1.42 Million
Q2 2021

Aug 12, 2021

BUY
$105.21 - $117.21 $82,063 - $91,423
780 Added 6.33%
13,109 $1.48 Million
Q1 2021

May 11, 2021

BUY
$102.3 - $112.62 $80,407 - $88,519
786 Added 6.81%
12,329 $1.34 Million
Q4 2020

Jan 25, 2021

SELL
$80.49 - $108.67 $214,505 - $289,605
-2,665 Reduced 18.76%
11,543 $1.24 Million
Q3 2020

Oct 22, 2020

BUY
$85.91 - $100.83 $51,374 - $60,296
598 Added 4.39%
14,208 $1.24 Million
Q2 2020

Jul 31, 2020

BUY
$73.37 - $98.18 $81,367 - $108,881
1,109 Added 8.87%
13,610 $1.34 Million
Q1 2020

Apr 23, 2020

BUY
$64.5 - $97.79 $15,286 - $23,176
237 Added 1.93%
12,501 $951,000
Q4 2019

Jan 22, 2020

BUY
$72.13 - $90.25 $6,203 - $7,761
86 Added 0.71%
12,264 $1.09 Million
Q3 2019

Oct 21, 2019

BUY
$62.98 - $75.72 $629 - $757
10 Added 0.08%
12,178 $922,000
Q2 2019

Jul 25, 2019

BUY
$65.7 - $83.98 $273,903 - $350,112
4,169 Added 52.12%
12,168 $886,000
Q1 2019

May 09, 2019

SELL
$77.14 - $90.79 $88,711 - $104,408
-1,150 Reduced 12.57%
7,999 $645,000
Q4 2018

Feb 04, 2019

BUY
$77.85 - $96.01 $48,578 - $59,910
624 Added 7.32%
9,149 $844,000
Q3 2018

Oct 30, 2018

BUY
$88.91 - $98.84 $68,460 - $76,106
770 Added 9.93%
8,525 $806,000
Q2 2018

Jul 19, 2018

BUY
$89.78 - $106.23 $77,121 - $91,251
859 Added 12.46%
7,755 $719,000
Q4 2017

Feb 02, 2018

SELL
$89.56 - $98.21 $109,084 - $119,619
-1,218 Reduced 15.01%
6,896 $667,000
Q3 2017

Nov 06, 2017

BUY
$69.85 - $89.22 $566,762 - $723,931
8,114
8,114 $720,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Ballentine Partners, LLC Portfolio

Follow Ballentine Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ballentine Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ballentine Partners, LLC with notifications on news.